AtriCure (NASDAQ:ATRC) Stock Bought Rep. Gilbert Ray Cisneros, Jr.

Posted by George Bondi on Sep 12th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in AtriCure stock on August 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

AtriCure Stock Up 3.0%

AtriCure stock traded up $1.58 during mid-day trading on Friday, reaching $54.54. The company’s stock had a trading volume of 1,098,844 shares, compared to its average volume of 835,279. The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of 259.73 and a beta of 1.26. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $55.72. The business’s 50 day simple moving average is $42.41 and its 200 day simple moving average is $33.55. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same period in the previous year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. BTIG Research lifted their target price on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. UBS Group reduced their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Needham & Company LLC raised their price target on AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $52.00.

Get Our Latest Stock Report on ATRC

Insider Buying and Selling

In other AtriCure news, insider Salvatore Privitera sold 3,657 shares of AtriCure stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00. Following the completion of the transaction, the insider directly owned 147,264 shares of the company’s stock, valued at $8,099,520. The trade was a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karen Prange sold 3,564 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares in the company, valued at approximately $884,989.20. This represents a 13.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 65,036 shares of company stock valued at $2,758,687. Insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. AQR Capital Management LLC lifted its stake in AtriCure by 1.0% in the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after purchasing an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in AtriCure by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after purchasing an additional 1,230 shares during the period. Goldman Sachs Group Inc. increased its position in AtriCure by 1.0% during the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after buying an additional 8,956 shares during the last quarter. Jane Street Group LLC increased its position in AtriCure by 658.3% during the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after buying an additional 87,553 shares during the last quarter. Finally, Strs Ohio bought a new stake in AtriCure in the first quarter valued at approximately $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.